Population immunity to varicella in Canada: A Canadian Immunization Research Network (CIRN) study

PLoS One. 2024 Aug 19;19(8):e0309154. doi: 10.1371/journal.pone.0309154. eCollection 2024.

Abstract

Introduction: The incidence of varicella in Canada has decreased by almost 99% since vaccination was introduced. However, variation in the timing and eligibility of vaccination programs across the country has resulted in some cohorts being under-vaccinated and therefore potentially susceptible to infection.

Methods: We used nationally representative specimens from the Biobank of Statistics Canada's Canadian Health Measures Survey (CHMS) as well as residual specimens from Ontario collected between 2009-2014 to estimate population immunity across age-groups and geography, and identify any groups at increased risk of varicella infection.

Results: The weighted proportion of specimens with antibody levels above the threshold of protection was 93.6% (95% CI: 92.4, 95.0). Protection was lowest among those aged 3-5 years (54.3%; 95% CI: 47.3, 61.4), but increased with age. Individuals born outside Canada had more than twice the odds of varicella susceptibility than those born in Canada (aOR: 2.7; 95% CI: 1.4, 5.0; p = 0.004). There were no differences by sex or geography within Canada, and there were no statistically significant differences when Ontario CHMS sera were compared to Ontario residual sera, apart from in participants aged 12-19 year age-group, for whom the CHMS estimate (91.2%; 95% CI: 86.7, 95.7) was significantly higher (p = 0.03) than that from residual specimens (85.9%, 95% CI: 81.1, 90.8).

Discussion: Varicella immunity in Canada is changing. Children appear to have low population immunity, placing them at greater risk of infection and at increased risk of severe disease as they age. Our results underscore the importance of performing periodic serosurveys to monitor further population immunity changes as the proportion of vaccine-eligible birth-cohorts increases, and to continually assess the risk of outbreaks.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Canada / epidemiology
  • Chickenpox Vaccine / immunology
  • Chickenpox* / epidemiology
  • Chickenpox* / immunology
  • Chickenpox* / prevention & control
  • Child
  • Child, Preschool
  • Female
  • Herpesvirus 3, Human / immunology
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Vaccination
  • Young Adult

Substances

  • Chickenpox Vaccine
  • Antibodies, Viral

Grants and funding

This study was funded by a grant awarded to SB from the Canadian Immunization Research Network (CIRN). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.